Dr. Brett Zbar, MD, serves as Managing Director and Global Head of Life Sciences at General Atlantic, a leading global growth equity firm providing capital and strategic support for growth companies.
Before joining General Atlantic in 2020, Brett was a managing director at Foresite Capital, where he focused on backing leading healthcare entrepreneurs and companies at all stages of development. While at Foresite, Brett served as a board member or observer at multiple companies, including ConnectiveRx, Kinnate Biopharma, ORIC Pharmaceuticals (OTCMKTS: OCLDY), Peloton Therapeutics (acquired by Merck & Co.), Pharvaris, Replimune (NASDAQ: REPL), Signant Health, Turning Point Therapeutics (NASDAQ: TPTX), and Venatorx Pharmaceuticals.
Prior to that, Brett was a partner at Aisling Capital, where he invested in life sciences companies developing and commercializing innovative products, services, and technologies.
Brett began his career at McKinsey & Company in the pharmaceutical and medical products practice and completed his internship in internal medicine on the Osler Medical Service at The Johns Hopkins Hospital. He received his MD from Harvard Medical School and holds a BA in English and molecular biophysics and biochemistry from Yale University.
